Company Statements October 7, 2023 Ionis statement about results from an analysis of exploratory cardiac endpoints in the Phase 3 NEURO-TTRansform study of eplontersen Read More October 7, 2023 Ionis statement about results from an analysis of exploratory cardiac endpoints in the Phase 3 NEURO-TTRansform study of eplontersen Read More January 23, 2023 Ionis’ statement about the FDA advisory committee meeting on tofersen Read More
October 7, 2023 Ionis statement about results from an analysis of exploratory cardiac endpoints in the Phase 3 NEURO-TTRansform study of eplontersen Read More
October 7, 2023 Ionis statement about results from an analysis of exploratory cardiac endpoints in the Phase 3 NEURO-TTRansform study of eplontersen Read More